Dupixent Lawsuit for T-Cell Lymphoma

Dupixent (dupilumab) is a biologic drug prescribed for conditions like atopic dermatitis and asthma, working by targeting specific immune pathways involved in allergic inflammation. It has offered relief to many individuals with moderate to severe eczema when topical treatments have proven ineffective, making it a commonly prescribed biologic medication for skin and respiratory ailments.

However, some patients have had a vastly different experience with Dupixent. Over the past several years, medical professionals and researchers have reported instances where patients treated with Dupixent were later diagnosed with cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma that primarily affects the skin. These reports have prompted increased investigation into whether Dupixent might worsen, accelerate, or mask CTCL in certain individuals.

Nguyen Injury Lawyer is currently evaluating potential Dupixent lawsuits on behalf of individuals who developed CTCL, mycosis fungoides, or Sézary syndrome after receiving Dupixent injections. Contact Nguyen Injury Lawyer today at XXX-XXX-XXXX or through our website at https://www.nguyeninjurylawyer.com or our contact page at https://www.nguyeninjurylawyer.com/contact.

What Is Cutaneous T-Cell Lymphoma?

Cutaneous T-cell lymphoma is a cancer of the immune system involving malignant T cells that migrate to the skin. In its initial stages, CTCL can be difficult to distinguish from eczema, psoriasis, or other chronic inflammatory skin conditions. It can present as ordinary rashes, plaques, itching, or redness that may flare up and fade away, seemingly like a manageable skin disorder rather than an underlying cancer.

This deceptive nature makes CTCL particularly dangerous. The disease can remain undetected for years, with inconclusive biopsies and symptoms resembling benign skin issues. Like a smoldering fire, CTCL can progress silently until it manifests in a more advanced stage, which is often more challenging to treat.

The most prevalent forms of CTCL are mycosis fungoides and Sézary syndrome. Both are serious conditions that can significantly impact a person’s life, often requiring ongoing treatment, and can be fatal in advanced stages.

How Dupixent Fits Into CTCL Allegations

The concern in Dupixent lymphoma lawsuits is not that Dupixent universally causes cancer. Rather, the allegation is that Dupixent can trigger, accelerate, or obscure CTCL in a subset of patients who were initially misdiagnosed with eczema or other inflammatory skin conditions.

In many reported cases, patients began using Dupixent for presumed dermatitis and initially experienced some improvement in their symptoms. This improvement reinforced the idea that the condition was inflammatory rather than malignant. However, over time, the disease progressed, worsened, or did not behave as typical eczema would. Subsequent testing then revealed the presence of CTCL.

Plaintiffs contend that by suppressing visible inflammation without addressing the underlying disease process, Dupixent may delay the diagnosis of CTCL, allowing the cancer to advance unchecked.

Why CTCL Gets Misdiagnosed as Eczema

A particularly troubling aspect of these cases is that early cutaneous T-cell lymphoma and atopic dermatitis can appear nearly identical, even to experienced dermatologists.

Both conditions can present with:

• Red, inflamed patches
• Itchy, scaly skin
• Lichenification (thickened, leathery texture)
• Fissuring and cracking
• Symptoms that flare and fade over time

This overlap in symptoms can lead to patients remaining on Dupixent for years while an undetected cancer quietly progresses.

Early-stage mycosis fungoides, the most common form of CTCL, often manifests as flat, scaly patches that respond partially to topical steroids, similar to eczema. Biopsies might yield inconclusive results. Patients and their doctors may mistakenly believe they are dealing with persistent dermatitis rather than a developing malignancy.

Dupixent can suppress the visible inflammation, causing redness to fade and itching to subside. This may create the impression that the drug is effective. However, if the underlying condition is CTCL rather than eczema, Dupixent could simply be masking the cancer’s symptoms while the disease continues to advance beneath the surface.

By the time the correct diagnosis is made, often after the cancer has progressed to a more advanced stage, treatment options become more limited, and outcomes are less favorable.

Plaintiffs allege that Regeneron and Sanofi-Aventis were aware of this diagnostic challenge and should have:

• Warned prescribers that CTCL can mimic atopic dermatitis
• Recommended ruling out lymphoma before initiating Dupixent in adult-onset or treatment-resistant cases
• Advised T-cell clonality testing or repeat biopsy when patients fail to respond as expected
• Included clear “stop and investigate” guidance when symptoms evolve atypically

However, the current Dupixent label does not contain this information.

What Dupixent Lawsuits Allege

Plaintiffs in Dupixent lymphoma lawsuits are making serious allegations against Regeneron and Sanofi-Aventis, primarily built on failure to warn claims and supported by growing scientific evidence.

The core allegations include:

• Dupixent caused, accelerated, or unmasked T-cell lymphoma, depending on the patient.
• The drug triggered cutaneous T-cell lymphoma (CTCL) or peripheral T-cell lymphoma (PTCL) in patients who had no prior cancer diagnosis, or accelerated disease progression in patients whose early-stage lymphoma was misdiagnosed as eczema.
• The manufacturers knew or should have known about the risk.
• Case reports, adverse event data submitted to the FDA, and peer-reviewed studies have documented the association between Dupixent and CTCL. This evidence was available to the companies well before injuries occurred.
• The U.S. label contains no warning about CTCL or PTCL.
• Despite mounting evidence, the current Dupixent prescribing information makes no mention of cutaneous T-cell lymphoma, peripheral T-cell lymphoma, mycosis fungoides, or Sézary syndrome.
• Atopic dermatitis and early CTCL look nearly identical.
• Both conditions present with red, itchy, scaly patches that flare and fade. Without explicit guidance to rule out lymphoma before prescribing Dupixent, especially in adults with atypical or treatment-resistant dermatitis, doctors may unknowingly treat a developing cancer.
• No guidance was provided to rule out lymphoma before treatment.
• Plaintiffs allege the companies failed to advise prescribers to consider T-cell clonality testing or skin biopsy in patients with adult-onset, refractory, or atypical dermatitis presentations.
• Continued treatment masked symptoms and delayed diagnosis.
• In many cases, patients experienced initial improvement on Dupixent, which reinforced the eczema diagnosis. However, suppressing visible inflammation without addressing the underlying malignancy allowed the cancer to progress unchecked, often to a more advanced and harder-to-treat stage.
• Patients would have made different choices with adequate warnings.
• Dupixent is prescribed for conditions that are uncomfortable but not life-threatening. If people had known about the lymphoma risk, they would have pursued additional testing, chosen alternative treatments, or never started the drug at all.

Nguyen Injury Lawyer believes that Regeneron and Sanofi-Aventis prioritized sales of a blockbuster drug over patient safety, resulting in unnecessary human suffering and death.

“No one told these patients that what looked like eczema might actually be something far more dangerous.”

Medical Evidence Being Cited in Dupixent CTCL Claims

Several studies and case series are frequently cited in connection with Dupixent lymphoma litigation. Observational database studies have reported higher rates of CTCL diagnoses among patients treated with dupilumab compared to similar patients who were not exposed to the drug.

Other reports include case series where patients treated with Dupixent for presumed eczema initially improved, then experienced disease progression consistent with CTCL. These patterns have been discussed in dermatology journals and conferences, particularly in patients with adult-onset or treatment-resistant dermatitis.

While no single study proves causation, plaintiffs argue that the collective evidence is strong enough that manufacturers should have provided clearer warnings and guidance to prescribers.

Dupixent by the Numbers

$14.1B – 2024 Global Sales

800K+ Patients Treated

9 FDA Indications

None CTCL Label Warning

Dupixent is a blockbuster biologic generating billions in annual revenue. Yet despite case reports linking it to T-cell lymphoma, the U.S. label contains no warning about CTCL or PTCL risk.

Are These Dupixent Lawsuits Class Actions?

Dupixent CTCL lawsuits are not class actions. Each patient’s case depends heavily on individual medical history, biopsy results, timing of Dupixent use, and disease progression. If enough cases are filed, the litigation could eventually be consolidated in federal multidistrict litigation for pretrial proceedings.

For now, these cases are being evaluated and filed individually.

Who May Qualify for a Dupixent Lawsuit?

You may have a viable Dupixent lawsuit if:

• You were prescribed Dupixent for eczema, asthma, or another approved use
• You were later diagnosed with cutaneous T-cell lymphoma
• Your condition worsened, progressed, or was delayed while on Dupixent
• You were diagnosed with mycosis fungoides or Sézary syndrome
• Your medical records show prolonged treatment despite atypical symptoms

Not every Dupixent patient with CTCL will qualify, but many cases deserve careful review. Contact Nguyen Injury Lawyer at XXX-XXX-XXXX to discuss your case.

What Happens Next in Dupixent Litigation?

Dupixent lawsuits are still in the early stages. Most activity right now involves medical record review, pathology evaluation, and case screening. As more cases are filed, courts may consider consolidation, coordinated discovery, and expert proceedings.

Patients considering a claim should not wait. Statutes of limitations apply, and delays can make cases harder to prove.

Are Lawyers Demanding a Dupixent Recall?

Whether there should be a Dupixent recall is a question beyond the scope of these lawsuits. The primary objective of these lawsuits is to ensure that doctors and patients are fully informed of the potential risks associated with Dupixent so they can make informed decisions about their treatment.

The core of these cases lies in the failure to warn. A manufacturer that is aware, or should be aware, that a subset of patients with adult-onset or refractory dermatitis may actually have early CTCL has a responsibility to communicate that risk. The specific content of the warning is straightforward: before initiating treatment in adults with atypical clinical courses and biopsy-suspicious lesions, consider T-cell clonality. After initiation, if the disease evolves in a way that is not typical for eczema, do not continue escalating dupilumab while “seeing if it helps.” Instead, stop and investigate. These messages align with approved labeling and the real-world cases now involved in the litigation.

While design defect is less obvious in a biologic case compared to a mechanical device case, it is still a possibility. Plaintiffs’ lawyers can argue that the risk mitigation design for dupilumab was defective because it did not incorporate safeguards for a known diagnostic gray zone.

In a situation where early mycosis fungoides can mimic eczema for years, a “safe” design includes comprehensive prescriber education, explicit biopsy recommendations in adult-onset disease, and clear stop rules when the clinical course deviates from typical eczema patterns. This represents risk management by design, and its absence is actionable when it predictably leads to delayed diagnosis and worse outcomes.

Nguyen Injury Lawyer will explore all of these aspects, but the core of the case will remain a failure to warn claim.

Current Status of Dupixent Lawsuits

As the saying goes, “Even a low-probability risk demands clear warning… especially when the cost of silence is a cancer diagnosis.”

Investigations and advertising for these cases have only recently begun, so we are in the initial stages. Currently, we are focused on gathering information and building records, rather than active litigation.

Will this result in a Dupixent class action lawsuit? While a traditional class action is unlikely, a federal multidistrict litigation (MDL) is probable. An MDL shares some characteristics with a class action but allows each survivor to maintain their individual claim.

To reach that point, individual Dupixent lawsuits must be filed across the country. Once a sufficient number of cases are filed, the Judicial Panel on Multidistrict Litigation can be petitioned to consolidate the cases before a single judge. This leads to case management orders, coordinated discovery, and a path toward bellwether trials.

The current situation is very early, likely earlier than many survivors would prefer. If the initial complaints are filed later in 2025 or 2026, MDL consolidation could occur within a year. Following that, discovery and expert evaluations will take another one to two years. Realistically, settlement pressure is still several years away.

This timeline can be disheartening for patients diagnosed with lymphoma. However, history indicates that once filings increase and the science is tested in court, these cases can progress faster than anticipated. The key point is that Dupixent lawsuits are just beginning to take shape. The actions taken now—collecting medical records, identifying clients, and engaging experts—will determine the strength of the litigation as it progresses. It is important to initiate your claim now to avoid statute of limitations issues or other problems that can arise from delays. Contact Nguyen Injury Lawyer at XXX-XXX-XXXX or visit our website at https://www.nguyeninjurylawyer.com to begin.

Who Is Eligible for a Dupixent Lawsuit?

Our attorneys at Nguyen Injury Lawyer are reviewing cases of patients who used Dupixent and later received a diagnosis of T-cell lymphoma. If you or a loved one fits this description, you may have a valid claim.

You may be eligible if:

• You were prescribed Dupixent for an approved condition such as eczema, asthma, chronic rhinosinusitis, eosinophilic esophagitis, prurigo nodularis, or COPD.
• You were subsequently diagnosed with:
  • Cutaneous T-cell lymphoma (CTCL)
  • Peripheral T-cell lymphoma (PTCL)
  • Mycosis fungoides
  • Sézary syndrome
• Your skin condition worsened, did not improve, or developed atypically while using Dupixent.
• Your lymphoma diagnosis was delayed while you continued Dupixent treatment.
• You had adult-onset dermatitis that was later reclassified as lymphoma.

Prioritized Cases

We are prioritizing cases based on the following diagnoses and descriptions:

Diagnosis	Description
CTCL	Cancer originating in T-cells that migrate to the skin.
PTCL	Systemic T-cell lymphoma affecting lymph nodes, blood, or organs.
Mycosis fungoides	Most common CTCL subtype, often mimicking eczema for years.
Sézary syndrome	Aggressive CTCL subtype involving skin, blood, and lymph nodes.

Not every Dupixent patient who develops lymphoma will qualify for a lawsuit. However, if you received Dupixent injections and were later diagnosed with any type of T-cell lymphoma, it is important to have your case carefully evaluated by Nguyen Injury Lawyer. Contact us at XXX-XXX-XXXX or through our contact page: https://www.nguyeninjurylawyer.com/contact.

The strongest cases often involve patients whose medical records show:

• Prolonged Dupixent use despite experiencing atypical symptoms.
• Initial improvement followed by disease progression.
• Delayed or missed lymphoma diagnosis.
• Lack of pre-treatment workup to rule out malignancy.

Statutes of limitations apply, so it is important to act quickly.

The deadline for filing a claim varies by state and may be based on the date of your diagnosis or when you first connected the diagnosis to Dupixent. Do not delay in finding out if you have a case. Contact Nguyen Injury Lawyer today.

Potential Dupixent Settlement Amounts

It is important to understand that any dollar figures provided at this stage are highly speculative, as this litigation is still in its early phases. Attorneys have only recently begun working on these cases, the science is still developing, regulatory bodies have not yet taken definitive action, and the litigation record that typically influences settlement negotiations is still being established. However, victims and their families deserve some context.

Civil lawsuits inherently assign a monetary value to suffering. The severity of the cancer, the intensity of treatment, and the extent of the manufacturer’s knowledge all influence outcomes. If medical records indicate that Dupixent contributed to accelerating or masking a lymphoma diagnosis, and if discovery reveals inadequate warnings, the liability for defendants becomes substantial. Conversely, if the documentation is less conclusive or the disease progression is ambiguous, settlement values will decrease.

Based on our current understanding, here are the early estimated ranges we believe are reasonable at this stage, assuming the cases are as successful as we anticipate:

• Early-stage CTCL with limited progression: Patients diagnosed early, treated with skin-directed therapies, achieving partial remission, requiring ongoing surveillance but without a dramatically shortened life expectancy.
  • Working settlement range: $100,000 to $300,000.
• Moderate disease with systemic therapy and ongoing morbidity: Patients requiring photopheresis, interferon, or systemic agents; significant skin involvement; relapsing course; substantial impact on work, family life, and mental health.
  • Working settlement range: $300,000 to $500,000.
• Advanced CTCL with aggressive treatment and shortened survival: Patients requiring chemotherapy, stem cell transplant consideration, or palliative regimens; severe decline in quality of life; extended hospitalizations; significant economic loss; risk of fatal outcome.
  • Working settlement range: $500,000 to $1.5 million.

These figures are not verdict predictions but rather settlement guidelines. A jury in a successful case could award tens of millions of dollars, especially in cases involving young patients, catastrophic financial losses, or evidence that the company ignored warning signs in the data. This potential for a large verdict creates pressure to settle in the first place.

For now, it’s important to recognize that Dupixent/CTCL lawsuits are not minor claims. These are serious cancer cases with treatments that juries understand and liability theories that are compelling. The manufacturers will eventually need to make significant payouts to resolve these claims or face the uncertainty of a trial.

Dupixent CTCL Lawsuit Settlement Ranges by Disease Severity

CTCL Severity	Common Treatments	Estimated Settlement Range
Early Stage CTCL	Topicals, Light Therapy	$50,000 – $300,000
Moderate Disease	Photopheresis, Interferon	$300,000 – $500,000
Advanced CTCL	Chemo, Stem Cell Transplant	$500,000 – $1.5 million

Example Dupixent Lawsuit

What happens when a medication marketed as a safe and transformative treatment for eczema and other inflammatory conditions is later accused of causing harm? A recently filed Dupixent lawsuit illustrates the arguments we are making in these cases.

Patients prescribed Dupixent for non-life-threatening conditions experienced limited long-term benefits and subsequently developed a rare and serious cancer known as cutaneous T-cell lymphoma. The primary allegation is not merely that the cancer occurred, but that it developed despite growing scientific evidence, adverse event reports, and clinical warnings that were not communicated to patients or doctors. Instead, the drug continued to be promoted as requiring no routine monitoring and posing fewer risks than older treatments.

These Dupixent cancer lawsuits center on a few key themes. Plaintiffs contend that Sanofi and Regeneron knew or should have known that Dupixent could cause, unmask, or accelerate CTCL, yet they failed to update warnings, labels, or prescribing guidelines. They highlight a pattern of initial improvement followed by worsening symptoms, delayed cancer diagnosis, and missed opportunities for earlier testing and intervention. The lawsuits also emphasize the disparity between the severity of the risk and the condition being treated, arguing that patients would have made different choices if they had been fully informed. These cases collectively assert that the issue was not an isolated incident but a systemic failure to warn while aggressively marketing a blockbuster drug.

What Should You Do Next?

If you or a loved one developed cutaneous T-cell lymphoma after taking Dupixent, it is crucial to have your case evaluated by a lawyer who understands both the medical and legal aspects of these claims. These cases are complex and require a nuanced understanding of clinical histories, immunological complexities, and evolving scientific evidence. Contact Nguyen Injury Lawyer at XXX-XXX-XXXX or visit our website at https://www.nguyeninjurylawyer.com. The good news is that you don’t have to navigate this alone.

The earlier your records are reviewed, the stronger your case will be, especially if your biopsy history is limited or your initial diagnosis was “eczema” that did not respond as expected. A lawyer experienced in pharmaceutical litigation can help you obtain your complete medical file, secure an independent pathology review if necessary, and establish a clear timeline for the courts and juries to follow.

If you have a viable claim, the next step is to protect your rights under the statute of limitations in your state. This deadline varies, but it typically begins from the time of diagnosis or when a reasonable person should have connected the diagnosis to the drug. Regardless, time is of the essence.

Unfortunately, these cases are unlikely to be resolved quickly. However, if the scientific evidence continues to strengthen and filings increase, there is a path to accountability. This path begins with a diagnosis, a timeline, and a decision to take action. Contact Nguyen Injury Lawyer today for a free consultation.

Latest Dupixent Lawsuit News and Updates

March 10, 2026

In a recent lawsuit, a couple from Snellville, Georgia, allege that Regeneron and Sanofi-Aventis failed to warn that Dupixent can cause, unmask, accelerate, or worsen cutaneous T-cell lymphoma, resulting in the wife developing mycosis fungoides after using the drug for what was initially diagnosed as eczema or atopic dermatitis.

According to the complaint, the wife began Dupixent injections on July 30, 2019, and continued until approximately June 2020. The suit claims she developed a skin rash that was treated as eczema, had no prior lymphoma diagnosis, and experienced only brief, minor improvement before her condition worsened, including the appearance of new spots and patches. She was diagnosed with mycosis fungoides in August 2020 and has since undergone treatment, including UVB light therapy, steroid injections, topical corticosteroids, and methotrexate.

The lawsuit asserts that the companies knew or should have known well before her treatment that Dupixent was associated with the development and rapid progression of cutaneous T-cell lymphoma, including mycosis fungoides and Sézary syndrome. It cites published case reports, observational studies, adverse event reports, and FDA safety-signal activity, alleging that the companies did not update the U.S. label. The complaint states that the prescribing information did not mention cutaneous T-cell lymphoma, advise physicians to rule out lymphoma before prescribing Dupixent, or instruct doctors to monitor patients whose skin disease failed to improve or worsened during treatment.

February 24, 2026

While the lymphoma litigation continues to grow, Dupixent also received another FDA approval. Sanofi and Regeneron announced that the FDA approved Dupixent for allergic fungal rhinosinusitis (AFRS) in adults and children aged 6 and older with a history of sino-nasal surgery, calling it the first and only medicine approved specifically for that condition. The companies stated that this is Dupixent’s ninth approved U.S. indication.

For further information or to discuss your potential case, please contact Nguyen Injury Lawyer at XXX-XXX-XXXX or visit our website at https://www.nguyeninjurylawyer.com.

Recent Developments in Dupixent Labeling and Litigation

The FDA’s approval in February 2026 is reflected in the current U.S. prescribing information for Dupixent. The updated label includes “Allergic Fungal Rhinosinusitis” as an approved indication and notes February 2026 as the date of the most recent significant change. However, a review of the current FDA label reveals no mention of “cutaneous T-cell lymphoma” or “malign” within the prescribing information.

Multidistrict Litigation (MDL) Filed: February 13, 2026

The Dupixent lymphoma litigation has progressed beyond individual lawsuits, with initial steps taken toward consolidation. On February 13, 2026, a proceeding titled “IN RE: Dupixent (Dupilumab) Products Liability Litigation,” MDL No. 3180, was officially filed with the Judicial Panel on Multidistrict Litigation. This filing date and case number are confirmed in the public docket entry.

This filing indicates that plaintiffs are formally seeking coordinated federal handling of Dupixent lymphoma cases. While a verified JPML transfer order was not found in the reviewed sources, the confirmed action is the filing of the MDL proceeding itself. As of yet, a specific district has not been designated for the transferred MDL.

Dupixent Approved for Bullous Pemphigoid: June 20, 2025

On June 20, 2025, Sanofi and Regeneron announced FDA approval of Dupixent for bullous pemphigoid. According to the companies’ press release, this approval made Dupixent the only targeted medicine approved in the U.S. for this condition. The approval was based on clinical data demonstrating improvements in sustained disease remission and reductions in both itch and oral corticosteroid use compared to a placebo.

The bullous pemphigoid approval highlights Dupixent’s continued commercial and regulatory expansion, even amidst emerging safety concerns regarding CTCL. At the time of the announcement, the companies reported that Dupixent had secured approval for eight distinct diseases in the United States.

Contact Nguyen Injury Lawyer About Your Dupixent Compensation Claim

If you have experienced serious side effects after using Dupixent, know that you are not alone, and legal recourse may be available. Nguyen Injury Lawyer can help you determine if you qualify to file a Dupixent lawsuit.

Contact Nguyen Injury Lawyer today for a free consultation. Call us at XXX-XXX-XXXX or contact us online to discuss your potential claim.